Asia Pac Allergy.  2012 Apr;2(2):115-121. 10.5415/apallergy.2012.2.2.115.

Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models

• Tamura T

• KMID: 2397364
• DOI: http://doi.org/10.5415/apallergy.2012.2.2.115

Abstract

BACKGROUND
Olopatadine hydrochloride ophthalmic solutions are treated for allergic conjunctival diseases that are a selective histamine H1 receptor antagonist and an inhibitor of the release of mediators including histamine from the human mast cells. Substance P (SP) levels are increased in tears of patients with allergic conjunctivitis. However, little is known about the regulation of SP release by anti-allergic ophthalmic solutions.
OBJECTIVE
We investigated that the effect of olopatadine hydrochloride ophthalmic solutions (olopatadine 0.1% and olopatadine 0.2%) on rat conjunctivitis models compared with other anti-allergic ophthalmic solutions.
METHODS
Conjunctivitis was induced by subconjunctival injection of histamine or intravenous injection of ovalbumin in rats passively sensitized with anti-ovalbumin anti-serum. The releases of SP were determined in the conjunctiva and tears using rat antigen-induced conjunctivitis models.
RESULTS
Olopatadine 0.1% and 0.2% significantly inhibited the increased conjunctival dye leaked in the histamine- or antigen-induced hyperpermeability. The inhibitory effects by olopatadine were more potent than by other tested anti-allergic ophthalmic solutions. Moreover, olopatadine significantly inhibited the release of SP from the conjunctiva.
CONCLUSION
These results indicate that olopatadine ophthalmic solutions appear to exert additional SP release inhibition besides dual-action such as selective histamine H1 receptor antagonistic action and mast cell stabilization action.

Keyword

Olopatadine hydrochloride; Ophthalmic solution; Substance P; Allergic conjunctivitis; Rat

MeSH Terms

Animals
Conjunctiva
Conjunctival Diseases
Conjunctivitis*
Conjunctivitis, Allergic
Histamine
Humans
Injections, Intravenous
Mast Cells
Olopatadine Hydrochloride*
Ophthalmic Solutions
Ovalbumin
Rats
Receptors, Histamine H1
Substance P*
Tears
Histamine
Olopatadine Hydrochloride
Ophthalmic Solutions
Ovalbumin
Receptors, Histamine H1
Substance P

Figure

• 

  Fig. 1 Effects of olopatadine ophthalmic solution 0.1% and 0.2% compared other anti-allergic ophthalmic solutions on histamine (A) or ovalbumin (B)-induced conjunctival vascular hyperpermeability in passively sensitized rats. Olopatadine 0.1%, olopatadine 0.2%, levocabastine 0.025%, and tranilast 0.5% were applied topically onto the eye 30 min before the challenge of antigen and histamine with Evans blue dye. Each column and vertical bar represents the mean ± SE of 8-11 rats. **p < 0.01, ***p < 0.001: significantly different from the control group (Student's t-test). ###p < 0.001: significantly different from the control group (Aspin Welch test).

• 

  Fig. 2 Effects of olopatadine ophthalmic solution 0.1% and 0.2% on ovalbumin-induced conjunctival vascular hyperpermeability in passively sensitized rats. Olopatadine ophthalmic solution 0.1% (olopatadine 0.1%), olopatadine ophthalmic solution 0.2% (olopatadine 0.2%) were applied topically onto the eyes 24 h, 6 h prior to the challenge of antigen, and 5 min after the challenge of antigen. Each column and vertical bar represents the mean ± SE of 4-7 rats. ***p < 0.001: significantly different from the control group (Student's t-test). ###p < 0.001: significantly different from the control group (Aspin Welch test).

• 

  Fig. 3 Effects of olopatadine ophthalmic solution compared other anti-allergic ophthalmic solution on substance P (SP) contents (A) and SP release (B) in conjunctiva induced by ovalbumin in passively sensitized rats. SP contents were measured 30 min after antigen challenge. Ophthalmic solutions were instilled at 30 min before antigen challenge and immediately after antigen challenge into the bilateral eye with 10 µL/site. Each column and vertical bar of SP contents (A) represents the mean ± SE of 7-9 rats. *p < 0.05, **p < 0.01: significantly different from the control group (Student's t-test). ††p < 0.01: significantly different from the pre group (Student's t-test).

• 

  Fig. 4 Effects of olopatadine ophthalmic solution and other anti-allergic ophthalmic solutions on substance P (SP) contents in tears induced by ovalbumin in passively sensitized rats. SP contents were measured 30 min after antigen challenge. Ophthalmic solutions were instilled at 30 min before antigen challenge and immediately after antigen challenge into the bilateral eye at 10 µL/site. Each column and vertical bar represents the mean ± SE of 5-7 rats. *p < 0.05, **p < 0.01, ***p < 0.001: significantly different from the control group (Student's t-test). †p < 0.05: significantly different from the olopatadine 0.1% group (Student's t-test).

Reference

1. Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther. 1996; 278:1252–1261. PMID: 8819509.

2. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996; 12:389–400. PMID: 8951675.

3. Yanni JM, Miller ST, Gamache DA, Spellman JM, Xu S, Sharif NA. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol. 1997; 79:541–545. PMID: 9433371.

4. Yanni JM, Weimer LK, Sharif NA, Xu SX, Gamache DA, Spellman JM. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol. 1999; 117:643–647. PMID: 10326962.

5. Fujishima H, Takeyama M, Takeuchi T, Saito I, Tsubota K. Elevated levels of substance P in tears of patients with allergic conjunctivitis and vernal keratoconjunctivitis. Clin Exp Allergy. 1997; 27:372–378. PMID: 9146929.

6. Micera A, Lambiase A, Bonini S. The role of neuromediators in ocular allergy. Curr Opin Allergy Clin Immunol. 2008; 8:466–471. PMID: 18769203.

7. Mantelli F, Micera A, Sacchetti M, Bonini S. Neurogenic inflammation of the ocular surface. Curr Opin Allergy Clin Immunol. 2010; 10:498–504. PMID: 20706114.

8. Rossi R, Johansson O. Cutaneous innervation and the role of neuronal peptides in cutaneous inflammation: a minireview. Eur J Dermatol. 1998; 8:299–306. PMID: 9683879.

9. Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Allergy Clin Immunol. 2011; 11:420–427. PMID: 21772138.

10. Tamura T, Amano T, Ohmori K, Manabe H. The effects of olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice. Eur J Pharmacol. 2005; 524:149–154. PMID: 16259975.

11. Murota H, El-latif MA, Tamura T, Amano T, Katayama I. Olopatadine hydrochloride improves dermatitis score and inhibits scratch behavior in NC/Nga mice. Int Arch Allergy Immunol. 2010; 153:121–132. PMID: 20407268.

12. Stotland LM, Share NN. Active bronchial anaphylaxis in the rat. Can J Physiol Pharmacol. 1974; 52:1114–1118. PMID: 4375539.

13. Minami K, Hossen MA, Kamei C. Increasing effect by simultaneous use of levocabastine and pemirolast on experimental allergic conjunctivitis in rats. Biol Pharm Bull. 2005; 28:473–476. PMID: 15744071.

14. Shimura M, Yasuda K, Miyazawa A, Otani T, Nakazawa T. Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis. Am J Ophthalmol. 2011; 151:697–702.e2. PMID: 21257151.

15. Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther. 1996; 12:401–407. PMID: 8951676.

16. Foreman J, Jordan C. Histamine release and vascular changes induced by neuropeptides. Agents Actions. 1983; 13:105–116. PMID: 6191537.

17. Mosimann BL, White MV, Hohman RJ, Goldrich MS, Kaulbach HC, Kaliner MA. Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients. J Allergy Clin Immunol. 1993; 92:95–104. PMID: 7687608.